Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lomitapide (AEGR-733) 是一种高效的微粒体甘油三酯转移蛋白(MTP)抑制剂,体内试验的IC50值为8 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 247 | 现货 | ||
2 mg | ¥ 369 | 现货 | ||
5 mg | ¥ 645 | 现货 | ||
10 mg | ¥ 993 | 现货 | ||
25 mg | ¥ 1,620 | 现货 | ||
50 mg | ¥ 2,360 | 现货 | ||
100 mg | ¥ 3,580 | 现货 | ||
200 mg | ¥ 5,130 | 现货 | ||
500 mg | ¥ 7,780 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 986 | 现货 |
产品描述 | Lomitapide (AEGR-733) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTP), an enzyme located in the lumen of the endoplasmic reticulum responsible for absorbing dietary lipids and transferring triglycerides onto apolipoprotein B (apo-B) in the assembly of very-low-density lipoprotein. |
靶点活性 | MTP:8 nM |
体外活性 | Lomitapide is an oral microsomal triglyceride transfer protein (MTP) inhibitor indicated for the treatment of patients with HoFH, a rare form of hypercholesterolemia that can lead to premature atherosclerotic disease. Lomitapide undergoes hepatic metabolism through cytochrome P-450 (CYP) isoenzyme 3A4 and interacts with CYP3A4 substrates including atorvastatin and simvastatin[2]. |
体内活性 | The use of lomitapide alone or in combination with other lipid-lowering modalities reduces plasma concentrations of low density lipoprotein cholesterol (LDL-C) by an average of more than 50%. Lomitapide is associated with significant gastrointestinal adverse effects and increases in hepatic fat levels. The bioavailability of the 50-mg lomitapide capsule is 7.1%. The mean half-life of lomitapide is 39.7 hours[2]. Single-dose administration of lomitapide is shown to reduce serum triglycerides by 35% and 47% at 0.3- and 1-mg/kg doses, respectively. Multiple-dose treatment with lomitapide also results in dose-dependent decrease in triglycerides (71%–87%), nonesterified fattyacids(33%–40%), and LDL-C(26-29%)[3]. |
别名 | AEGR-733, 洛美他派, BMS-201038 |
分子量 | 693.72 |
分子式 | C39H37F6N3O2 |
CAS No. | 182431-12-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (134.3 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: 93 mg/mL (134.3 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 1.4415 mL | 7.2075 mL | 14.415 mL | 36.0376 mL |
5 mM | 0.2883 mL | 1.4415 mL | 2.883 mL | 7.2075 mL | |
10 mM | 0.1442 mL | 0.7208 mL | 1.4415 mL | 3.6038 mL | |
20 mM | 0.0721 mL | 0.3604 mL | 0.7208 mL | 1.8019 mL | |
50 mM | 0.0288 mL | 0.1442 mL | 0.2883 mL | 0.7208 mL | |
100 mM | 0.0144 mL | 0.0721 mL | 0.1442 mL | 0.3604 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lomitapide 182431-12-5 Metabolism CETP AEGR 733 BMS 201038 Inhibitor AEGR733 BMS201038 AEGR-733 洛美他派 inhibit BMS-201038 inhibitor